Biotransformation In Drug Discovery | 4873
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Biotransformation in drug discovery

3rd World Congress on Biotechnology

Selvan Ravindran

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.009

Biotransformation is a process by which organic compounds are converted from one form to another with the aid of organisms such as enzymes, bacteria and fungi. In the drug discovery programme biotransformations are used as a valuable strategy to build molecules similar to parent drug. Biotransformations can also be used to synthesize molecules which are difficult by synthetic approaches. Microbial biotransformations are widely used to generate metabolites in gram quantities. Biotransformation and synthetic approaches in tandem serves as a vital source for generating compounds around core structures which can be screened for various activity studies to advance the compounds. During pre-clinical stage, information from biotransformation experiments can be effectively utilized to synthesize more back-up compounds. Sulfonylurea urea drugs were incubated with hepatic microsomes to produce metabolites. For example one of the sulfonylurea urea drugs in the market shows new metabolites which are characterized using liquid chromatography and mass spectrometry. Liquid chromatography is used to separate the formed metabolites. Fragmentation pattern from the mass spectrum is utilized to identify the biotransformation site in the molecule which is the metabolic soft spot. Neutral loss scan in the mass spectrometer is used to identify adducts of the drugs. Identified new metabolites are structurally similar to parent drugs implying the possibility of better therapeutic effects. Formed new metabolites are due to the activity of different type of enzymes in hepatic microsomes.
Selvan Ravindran is a Senior Research Scientist in Sai Life Sciences Limited, Pune, India. He received his Ph.D degree from Indian Institute of Technology (Chennai). He did his postdoctoral studies in University of Texas Medical Branch, USA and University of Arizona, USA. He also worked as a Biotransformation Scientist in Biocon Bristol Myers and Squibb Research Centre in Bangalore. His major areas of research interests are Biotransformation (Metabolite identification using liquid chromatography and mass spectrometry), Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetics). He has published more than 10 research papers in reputed journals and presented more than 15 papers in national and international conferences.